Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

ELOXX PHARMACEUTICALS ($ELOX) Releases Q3 2026 Earnings

None

ELOXX PHARMACEUTICALS ($ELOX) posted quarterly earnings results for Q3 2026 on Monday, November 16th. The company reported earnings of -$0.49 per share, beating estimates of -$0.59 by $0.10. The company also reported revenue of $0, equaling estimates of $0 by $0.

Stock price change since market open this morning: -3.8%

You can see Quiver Quantitative's $ELOX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

EARLY ACCESS
Receive ELOX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

ELOXX PHARMACEUTICALS Hedge Fund Activity

We have seen 7 institutional investors add shares of ELOXX PHARMACEUTICALS stock to their portfolio, and 6 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

ELOXX PHARMACEUTICALS Analyst Ratings

Wall Street analysts have issued reports on $ELOX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Guggenheim issued a "Buy" rating on 10/28/2026
  • Cantor Fitzgerald issued a "Overweight" rating on 10/15/2026
  • Leerink Partners issued a "Outperform" rating on 09/18/2026
  • LUCID CAPITAL MARKETS issued a "Buy" rating on 08/20/2026
  • LifeSci Capital issued a "Outperform" rating on 07/22/2026

To track analyst ratings and price targets for ELOXX PHARMACEUTICALS, check out Quiver Quantitative's $ELOX forecast page.

ELOXX PHARMACEUTICALS Price Targets

Multiple analysts have issued price targets for $ELOX recently. We have seen 4 analysts offer price targets for $ELOX in the last 6 months, with a median target of $39.0.

Here are some recent targets:

  • Vamil Divan from Guggenheim set a target price of $40.0 on 10/28/2026
  • Joseph Schwartz from Leerink Partners set a target price of $32.0 on 09/18/2026
  • Dev Prasad from LUCID CAPITAL MARKETS set a target price of $38.0 on 08/20/2026
  • Rami Katkhuda from LifeSci Capital set a target price of $40.0 on 07/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles